|
Title
|
|
|
|
Circulating Transforming Growth Factor-beta in Marfan Syndrome
| |
|
Author
|
|
|
|
| |
|
Institution/Organisation
|
|
|
|
GenTAC Consortium
| |
|
Abstract
|
|
|
|
| Background-Marfan syndrome (MFS) is caused by mutations in the fibrillin-1 gene and dysregulation of transforming growth factor-beta (TGF-beta). Recent evidence suggests that losartan, an angiotensin II type 1 blocker that blunts TGF-beta activation, may be an effective treatment for MFS. We hypothesized that dysregulation of TGF-beta might be mirrored in circulating TGF-beta concentrations. Methods and Results-Serum obtained from MFS mutant mice (Fbn1(C1039G/+)) treated with losartan was analyzed for circulating TGF-beta 1 concentrations and compared with those from placebo-treated and wild-type mice. Aortic root size was measured by echocardiography. Data were validated in patients with MFS and healthy individuals. In mice, circulating total TGF-beta 1 concentrations increased with age and were elevated in older untreated Fbn1(C1039G/+) mice compared with wild-type mice (P = 0.01; n = 16; mean +/- SEM, 115 +/- 8 ng/mL versus n = 17; mean +/- SEM, 92 +/- 4 ng/mL). Losartan-treated Fbn1(C1039G/+) mice had lower total TGF-beta 1 concentrations compared with age-matched Fbn1(C1039G/+) mice treated with placebo (P = 0.01; n = 18; 90 +/- 5 ng/mL), and circulating total TGF-beta 1 levels were indistinguishable from those of age-matched wild-type mice (P = 0.8). Correlation was observed between circulating TGF-beta 1 levels and aortic root diameters in Fbn1(C1039G/+) and wild-type mice (P = 0.002). In humans, circulating total TGF-beta 1 concentrations were elevated in patients with MFS compared with control individuals (P < 0.0001; n = 53; 15 +/- 1.7 ng/mL versus n = 74; 2.5 +/- 0.4 ng/mL). MFS patients treated with losartan (n = 55) or beta-blocker (n = 80) showed significantly lower total TGF-beta 1 concentrations compared with untreated MFS patients (P <= 0.05). Conclusions-Circulating TGF-beta 1 concentrations are elevated in MFS and decrease after administration of losartan, beta-blocker therapy, or both and therefore might serve as a prognostic and therapeutic marker in MFS. (Circulation. 2009;120:526-532.) |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Circulation / American Heart Association. - New York, N.Y.
| |
|
Publication
|
|
|
|
New York, N.Y.
:
2009
| |
|
ISSN
|
|
|
|
0009-7322
| |
|
DOI
|
|
|
|
10.1161/CIRCULATIONAHA.108.841981
| |
|
Volume/pages
|
|
|
|
120
:6
(2009)
, p. 526-532
| |
|
ISI
|
|
|
|
000268813300010
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|